Literature DB >> 2065115

Issues surrounding the assessment of the genetic determinants of drugs as reinforcing stimuli.

J M Carney1, M S Cheng, C Wu, T W Seale.   

Abstract

A wide variety of drugs used in medicine and on a non-prescription basis have abuse liability. However, not all psychoactive drugs have demonstrable reinforcing properties either in animal models or in humans. In order to predict the abuse liability of a compound or to understand determinants of the abuse liability, several animal testing procedures have been developed. These procedures include tests for physical dependence, tolerance, disruption of ongoing behaviors, discriminative stimulus properties, and the direct or indirect assessment of the reinforcement. While tests for the production of tolerance and physical dependence may not predict abuse liability, they would significantly modify the abuse risk. This paper will focus on the methods available for the assessment of the reinforcing properties and the advantages of using genetically defined mice to better understand the determinants of the reinforcing properties and to isolate phenotypes that are hyper-responsive and hypo-responsive to the reinforcing properties of drugs under study. Examples of genetically determined differences are provided and areas of inadequate information are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2065115     DOI: 10.1300/J069v10n01_11

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  3 in total

1.  Variations in cocaine self-administration by inbred rat strains under a progressive-ratio schedule.

Authors:  A S Ward; D H Li; R R Luedtke; M W Emmett-Oglesby
Journal:  Psychopharmacology (Berl)       Date:  1996-10       Impact factor: 4.530

2.  Oral etonitazene and cocaine consumption by AA, ANA and Wistar rats.

Authors:  P Hyyatiä; J D Sinclair
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

3.  Voluntary consumption of morphine in 15 inbred mouse strains.

Authors:  J K Belknap; J C Crabbe; J Riggan; L A O'Toole
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.